Drug Discovery
BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish...
February 28, 2024 | News
Collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases ...
March 27, 2024 | News
This partnership aims to enhance therapeutic discovery and expedite the journey to Investigational New Drug (IND) submission by combining Charles R...
February 23, 2024 | News
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") has announced a strategic partnership with the AI-driven company InveniAI...
February 22, 2024 | News
Hox Therapeutics Ltd, a pioneering biotechnology company dedicated to developing targeted cancer therapies, and Vernalis (R&D) Ltd, a renowned subsidia...
February 22, 2024 | News
Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth appr...
February 17, 2024 | News
Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for A...
February 15, 2024 | News
Kevin Green, Chief Operating Officer of Elsie Biotechnologies, expressed enthusiasm, stating, "We are pleased that GSK ha...
February 15, 2024 | News
Lupus nephritis, a condition affecting the kidneys, presents a challenging treatment landscape with limited efficacy from existing therapies. ATA32...
February 15, 2024 | News
BioAge Labs (“BioAge”), a pioneering biotechnology firm dedicated to advancing novel treatments for obesity and metabolic diseases by e...
February 14, 2024 | News
VantAI, a trailblazer in artificial intelligence (AI)-enabled drug discovery, has announced a groundbreaking collaboration with pharmaceutical giant Bristo...
February 14, 2024 | News
This groundbreaking achievement marks mazdutide as the first GLP-1R/GCGR dual agonist to successfully complete Phase 3 trials in support of an NDA ...
February 08, 2024 | Regulatory
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety conce...
February 05, 2024 | News
The lead investor is China Development Industrial Bank (CDIB), with significant contributions from Taian Venture Capital, Maxpro and the National Developme...
February 01, 2024 | News
Most Read
Bio Jobs
News
Editor Picks